Harbour BioMed HBM9378 Phase I data: does long-acting TSLP inhibition change asthma treatment economics?
Harbour BioMed’s HBM9378 Phase I data shows long half-life and safety. Find out what this means for asthma, COPD, and TSLP competition.
Phase 3 CYPRESS miss forces Theravance Biopharma to rethink pipeline and accelerate strategic alternatives
Theravance Biopharma halted its ampreloxetine program after a Phase 3 failure. Discover what the CYPRESS results mean for the company and the neurogenic hypotension market.